<author><surname>Asplund </surname><given-names>K</given-names></author>,<author> <surname>Ashburner </surname><given-names>S</given-names></author>, <author><surname>Cargill </surname><given-names>K</given-names></author>,<author> <surname>Hux </surname><given-names>M</given-names></author>, <author><surname>Lees </surname><given-names>K</given-names></author>, <author><surname>Drummond </surname><given-names>M</given-names></author>,<other> et al</other> (<year>2003</year>) <title>Health care resource use and stroke outcome</title>. <source>Multinational comparisons within the GAIN International trial. Int J Technol Assess Health Care</source> <volume>19</volume> (<fpage>2):267</fpage> - <lpage>277</lpage>
<author><surname>Bastian </surname><given-names>H</given-names></author>,<author> <surname>Bender </surname><given-names>R</given-names></author>, <author><surname>Ernst </surname><given-names>AS</given-names></author>, <author><surname>Kaiser </surname><given-names>T</given-names></author>, <author><surname>Kirchner </surname><given-names>H</given-names></author>, <author><surname>KolominskyRabas </surname><given-names>P</given-names></author>,<author> <surname>Lange </surname><given-names>S</given-names></author>, <author><surname>Sawicki </surname><given-names>PT</given-names></author>, <author><surname>Weber </surname><given-names>M </given-names></author>(<year>2006</year>) <title>Methoden</title>. <other>Köln</other>:<publisher> Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</publisher>. <other>Report No.</other>: version <volume>2.0</volume>
<author><surname>Bryan </surname><given-names>S</given-names></author>, <author><surname>Brown </surname><given-names>J </given-names></author>(<year>1998</year>) <title>Extrapolation of cost-effectiveness information to local settings</title>. <source>J Health Serv Res Policy</source> <volume>3</volume> (<issue>2</issue>):<fpage>108</fpage> - <lpage>112</lpage>
<author><surname>Bytzer </surname><given-names>P </given-names></author>(<year>1999</year>) <title>Cost-effectiveness of gastroscopy</title>. <source>Ital J Gastroenterol Hepatol</source> <volume>31</volume> (<issue>8</issue>):<fpage>749 </fpage>- <lpage>760</lpage>
<author><surname>Claxton </surname><given-names>K</given-names></author>, <author><surname>Sculpher </surname><given-names>M</given-names></author>, <author><surname>McCabe </surname><given-names>C</given-names></author>, <author><surname>Briggs </surname><given-names>A</given-names></author>, <author><surname>Akehurst </surname><given-names>R</given-names></author>, <author><surname>Buxton </surname><given-names>M</given-names></author>, <author><surname>Brazier </surname><given-names>J</given-names></author>, <author><surname>O’Hagan</surname> <given-names>T </given-names></author>(<year>2005</year>) <title>Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra</title>. <source>Health Econ</source> <volume>14</volume> (<issue>4</issue>):<fpage>339 </fpage>- <lpage>347</lpage>
<author><surname>Cook </surname><given-names>JR</given-names></author>, <author><surname>Drummond </surname><given-names>M</given-names></author>,<author> <surname>Glick </surname><given-names>H</given-names></author>, <author><surname>Heyse </surname><given-names>JF</given-names></author> (<year>2003</year>) <title>Assessing the appropriateness of combining economic data from multinational clinical trials</title>. <source>Stat Med</source> <volume>22</volume> (<issue>12</issue>):<fpage>1955 </fpage>- <lpage>1976</lpage>
<author><surname>Demol </surname><given-names>P</given-names></author>, <author><surname>Weihrauch </surname><given-names>TR</given-names></author> (<year>1997</year>) <title>Multi-national clinical therapy studies. Design, management and costs (in German</title>). <other>Med Klin (Munich)</other> <volume>92</volume> (<issue>2</issue>):<fpage>117 </fpage>- <lpage>123</lpage>
<author><surname>Drummond </surname> <given-names>MF</given-names></author>,<author> <surname>Pang</surname> <given-names>F </given-names></author>(<year>2001</year>) <title>Transferability of economic evaluation results</title>. In: <editor>Drummond MF</editor>, <editor>McGuire A</editor> (eds) <source>Economic evaluation in health care: merging theory with practice</source>. <publisher>Oxford University Press</publisher>, <other>Oxford</other>
<author><surname>Drummond </surname><given-names>MF</given-names></author>, <author><surname>O’Brien</surname> <given-names>BJ</given-names></author>, <author><surname>Stoddart </surname><given-names>GL</given-names></author>, <author><surname>Torrance </surname><given-names>GW </given-names></author>(<year>1997</year><author>) </author><title>Methods for economic evaluation of health care programmes, 2nd edn</title><author>. </author><publisher>Oxford University Press</publisher><author>, </author><other>Oxford</other>
<author><surname>Grieve </surname><given-names>R</given-names></author>, <author><surname>Nixon </surname><given-names>R</given-names></author>, <author><surname>Thompson </surname><given-names>SG</given-names></author>, <author><surname>Normand </surname><given-names>C </given-names></author>(<year>2005</year>) <title>Using multilevel models for assessing the variability of multinational resource use and cost data</title>. <source>Health Econ</source> <volume>14</volume> (<issue>2</issue>):<fpage>185 </fpage>- <lpage>196</lpage>
<author><surname>Halliday </surname><given-names>RG</given-names></author>, <author><surname>Darba </surname><given-names>J </given-names></author>(<year>2003</year>) <title>Cost data assessment in multinational economic evaluations: some theory and review of published studies</title>. <source>Appl Health Econ Health Policy</source> <volume>2</volume> (<issue>3</issue>):<fpage>149 </fpage>- <lpage>155</lpage>
<author><surname>Hay </surname><given-names>J</given-names></author>, <author><surname>Jackson</surname> <given-names>J </given-names></author>(<year>1999</year>) <title>Panel 2: methodological issues in conducting pharmacoeconomic evaluations-modeling studies</title>. <source>Value Health</source> <volume>2</volume> (<issue>2</issue>):<fpage>78 </fpage>- <lpage>81</lpage>
<author><surname>Heyland </surname><given-names>DK</given-names></author>, <author><surname>Kernerman </surname><given-names>P</given-names></author>, <author><surname>Gafni </surname><given-names>A</given-names></author>, <author><surname>Cook </surname><given-names>DJ </given-names></author>(<year>1996</year>) <title>Economic evaluations in the critical care literature: do they help us improve the efficiency of our unit</title>? <source>Crit Care Med</source> <volume>24</volume> (<issue>9</issue>):<fpage>1591</fpage> - <lpage>1598</lpage>
<author><surname>Hjelmgren </surname><given-names>J</given-names></author>, <author><surname>Berggren </surname><given-names>F</given-names></author>, <author><surname>Andersson </surname><given-names>F</given-names></author> (<year>2001</year>) <title>Health economic guidelines—similarities, differences and some implications</title>. <source>Value Health</source> <volume>4</volume> (<issue>3</issue>):<fpage>225 </fpage>- <lpage>250</lpage>
<author><surname>Jönsson </surname><given-names>B</given-names></author>, <author><surname>Weinstein </surname><given-names>MC </given-names></author>(<year>1997</year>) <title>Economic evaluation alongside multinational clinical trials. Study considerations for GUSTO IIb</title>. <source>Int J Technol Assess Health Care</source> <volume>13</volume> (<issue>1</issue>):<fpage>49 </fpage>- <lpage>58</lpage>
<author><surname>Kaplan </surname><given-names>GA</given-names></author>, <author><surname>Keil </surname><given-names>JE </given-names></author>(<year>1993</year>) <title>Socioeconomic factors and cardiovascular disease: a review of the literature</title>. <source>Circulation</source> <volume>88</volume> (<issue>4 Pt 1</issue>):<fpage>1973</fpage>- <lpage>1998</lpage>
<author><surname>Koopmanschap </surname><given-names>MA</given-names></author>, <author><surname>Touw </surname><given-names>KC</given-names></author>, <author><surname>Rutten </surname><given-names>FF </given-names></author>(<year>2001</year>) <title>Analysis of costs and cost-effectiveness in multinational trials</title>. <source>Health Policy</source> <volume>58</volume> (<issue>2</issue>):<fpage>175 </fpage>- <lpage>186</lpage>
<author><surname>Manca </surname><given-names>A</given-names></author>, <author><surname>Willan </surname><given-names>AR </given-names></author>(<year>2006</year>) ‘<title>Lost in translation’: accounting for between-country differences in the analysis of multinational costeffectiveness data</title>. <source>Pharmacoeconomics</source> <volume>24</volume> (<issue>11</issue>):<fpage>1101 </fpage>- <lpage>1119</lpage>
<author><surname>Menzin </surname><given-names>J</given-names></author>, <author><surname>Oster </surname><given-names>G</given-names></author>, <author><surname>Davies </surname><given-names>L</given-names></author>, <author><surname>Drummond </surname><given-names>MF</given-names></author>, <author><surname>Greiner </surname><given-names>W</given-names></author>, <author><surname>Lucioni </surname><given-names>C</given-names></author>, <author><surname>Merot </surname><given-names>JL</given-names></author>, <author><surname>Rossi </surname><given-names>F</given-names></author>, <author><surname>vd Schulenburg</surname> <given-names>JG</given-names></author>, <author><surname>Souêtre </surname><given-names>E </given-names></author>(<year>1996</year>) <title>A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis</title>. <source>Int J Technol Assess Health Care</source> <volume>12</volume> (<issue>1</issue>):<fpage>52 </fpage>- <lpage>61</lpage>
<author><surname>Moayyedi </surname><given-names>P </given-names></author>(<year>2007</year>) <title>The health economics of Helicobacter pylori infection</title>. <source>Best Pract Res Clin Gastroenterol</source> <volume>21</volume> (<issue>2</issue>):<fpage>347 </fpage>- <lpage>361</lpage>
<author><surname>O’Brien</surname> <given-names>BJ </given-names></author>(<year>1997</year>) <title>A tale of two (or more) cities: geographic transferability of pharmacoeconomic data</title>. <source>Am J Manag Care</source> <volume>3</volume> (Suppl):<fpage>S33</fpage>-<lpage>S39</lpage>
<editor>Ontario Ministry of Health and Long-Term Care</editor> (<year>1994</year>) <title>Ontario guidelines for economic analysis of pharmaceutical products</title>. <publisher>Queen’s Printer for Ontario</publisher>
<author><surname>Pang </surname><given-names>F </given-names></author>(<year>2002</year>) <title>Design, analysis and presentation of multinational economic studies: the need for guidance</title>. <source>Pharmacoeconomics</source> <volume>20</volume> (<issue>2</issue>):<fpage>75 </fpage>- <lpage>90</lpage>
<author><surname>Pinto </surname><given-names>EM</given-names></author>, <author><surname>Willan </surname><given-names>AR</given-names></author>, <author><surname>O’Brien</surname> <given-names>BJ </given-names></author>(<year>2005</year>) <title>Cost-effectiveness analysis for multinational clinical trials</title>. <source>Stat Med</source> <volume>24</volume> (<issue>13</issue>):<fpage>1965 </fpage>- <lpage>1982</lpage>
<author><surname>Reed </surname><given-names>SD</given-names></author>, <author><surname>Anstrom </surname><given-names>KJ</given-names></author>, <author><surname>Bakhai </surname><given-names>A</given-names></author>, <author><surname>Briggs </surname><given-names>AH</given-names></author>, <author><surname>Califf </surname><given-names>RM</given-names></author>, <author><surname>Cohen </surname><given-names>DJ</given-names></author>, <author><surname>Drummond</surname> <given-names>MF</given-names></author>, <author><surname>Glick</surname> <given-names>HA</given-names></author>, <author><surname>Gnanasakthy </surname><given-names>A</given-names></author>, <author><surname>Hlatky </surname><given-names>MA </given-names></author><other>et al</other> (<year>2005</year>) <title>Conducting economic evaluations alongside multinational clinical trials: toward a research consensus</title>. <other>Am Heart J</other> <volume>149</volume> (<issue>3</issue>):<fpage>434 </fpage>- <lpage>443</lpage>
<author><surname>Schöffski </surname><given-names>O</given-names></author>, <author>Graf von der Schulenburg <given-names>JM </given-names></author>(<year>2007</year>) <title>Die Standardisierung der Methodik: Guidelines</title>. In: <source>Gesundheitsökonomische Evaluationen,</source> <volume>3</volume> ed. <publisher>Spinger</publisher>, <other>Berlin</other>, pp <fpage>471</fpage> - <lpage>489</lpage>
<author><surname>Sculpher </surname><given-names>MJ</given-names></author>, <author><surname>Pang </surname><given-names>FS</given-names></author>, <author><surname>Manca </surname><given-names>A</given-names></author>, <author><surname>Drummond </surname><given-names>MF</given-names></author>, <author><surname>Golder </surname><given-names>S</given-names></author>,<author> <surname>Urdahl </surname><given-names>H</given-names></author>, <author><surname>Davis </surname><given-names>LM</given-names></author>, <author><surname>Eastwood </surname><given-names>A </given-names></author>(<year>2004</year>) <title>Generalisability in economic evaluation studies in healthcare: a review and case studies</title>. <source>Health Technol Assess</source> <volume>8</volume> (<issue>49</issue>):<fpage>iii</fpage>-<lpage>iv</lpage>
<author><surname>Siebert </surname><given-names>U</given-names></author> (<year>2003</year>) <title>When should decision-analytic modeling be used in the economic evaluation of health care</title>? <source>Eur J Health Econ</source> <issue>4</issue>:<fpage>143 </fpage>- <lpage>150</lpage>
<author><surname>Thompson </surname><given-names>SG</given-names></author>, <author><surname>Nixon </surname><given-names>RM</given-names></author>, <author><surname>Grieve </surname><given-names>R </given-names></author>(<year>2006</year>) <title>Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study</title>. <source>J Health Econ</source> <volume>25</volume> (<issue>6</issue>):<fpage>1015 </fpage>- <lpage>1028</lpage>
<author><surname>Willan </surname><given-names>AR</given-names></author>, <author><surname>Pinto </surname><given-names>EM</given-names></author>, <author><surname>O’Brien </surname><given-names>BJ</given-names></author>, <author><surname>Kaul </surname><given-names>P</given-names></author>, <author><surname>Goeree </surname><given-names>R</given-names></author>, <author><surname>Lynd </surname><given-names>L</given-names></author>, <author><surname>Armstrong </surname><given-names>PW </given-names></author>(<year>2005</year>) <title>Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis</title>. <source>Health Econ</source> <volume>14</volume> (<issue>4</issue>):<fpage>327 </fpage>- <lpage>338</lpage>
<author><surname>Willke </surname><given-names>RJ</given-names></author>, <author><surname>Glick </surname><given-names>HA</given-names></author>, <author><surname>Polsky </surname><given-names>D</given-names></author>, <author><surname>Schulman </surname><given-names>K </given-names></author>(<year>1998</year>) <title>Estimating country-specific cost-effectiveness from multinational clinical trials</title>. <source>Health Econ</source> <volume>7</volume> (<issue>6</issue>):<fpage>481 </fpage>- <lpage>493</lpage>
